Research Topics
| D DodickSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Headache as a symptom of ominous disease. What are the warning signals?D Dodick
Mayo Clinic, Rochester, MN 55905, USA
Postgrad Med 101:46-50, 55-6, 62-4. 1997..These should prompt further investigation with MRI and/or lumbar puncture...- A review of the clinical efficacy and tolerability of almotriptan in acute migraineDavid W Dodick
Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
Expert Opin Pharmacother 4:1157-63. 2003..Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification. Almotriptan can be recommended as first-line treatment for acute migraine... - Migraine preventionD W Dodick
Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
Pract Neurol 7:383-93. 2007..Rational combinations of preventive medications may also be useful. This review provides an evidence and experience-based approach to the preventive treatment of migraine... - Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled studyDavid Dodick
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
CNS Drugs 19:125-36. 2005..The objective of this study was to assess the efficacy, speed of onset and tolerability of the nasal spray formulation of zolmitriptan in migraine treatment... - Indomethacin-responsive headache syndromesDavid W Dodick
Department of Neurology, Mayo Medical School, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
Curr Pain Headache Rep 8:19-26. 2004..Hypnic headache recently has been described as another primary headache disorder that may respond to indomethacin... - Triptans and chest symptoms: the role of pulmonary vasoconstrictionD W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
Cephalalgia 24:298-304. 2004..Pre-clinical studies of isolated pulmonary blood vessels may predict the clinical likelihood of chest symptoms; however, additional comparisons are needed... - Applying the benefits of the AwM study in the clinicD W Dodick
Mayo Clinic, Scottsdale, AZ, USA
Cephalalgia 28:42-9. 2008.... - Pearls: headacheDavid W Dodick
Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA
Semin Neurol 30:74-81. 2010..Knowing some simple rules and standard questions will make the process almost fail proof... - Triptans and CNS side-effects: pharmacokinetic and metabolic mechanismsD W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
Cephalalgia 24:417-24. 2004..If CNS side-effects are a clinically relevant concern in the individual patient, use of a triptan with a low incidence of CNS side-effects may offer the potential for earlier initiation of treatment and more effective outcomes... - Botulinum neurotoxin for the treatment of migraine and other primary headache disordersDavid Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Clin Dermatol 22:76-81. 2004..These studies may provide further evidence that BoNT/A is an effective option for the preventive treatment of migraine... - Advances in migraine management: implications for managed care organizationsDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
Manag Care 13:45-51. 2004..The improved clinical profiles of the triptans provide substantial value to managed care organizations... - Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR ProjectDavid W Dodick
Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA
Curr Pain Headache Rep 8:435-42. 2004..Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials... - Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptanDavid W Dodick
Department of Neurology, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA
Cephalalgia 31:296-300. 2011..Sustained pain-free response with no adverse events has been recommended as a composite endpoint which measures the efficacy and tolerability attributes that patients desire... - Clinical practice. Chronic daily headacheDavid W Dodick
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Ariz 85259, USA
N Engl J Med 354:158-65. 2006 - Recurrent short-lasting headache associated with paroxysmal hypertension: a clonidine-responsive syndromeD W Dodick
Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
Cephalalgia 20:509-14. 2000..The pathophysiology of this syndrome and the mechanism of clonidine action are reviewed in the context of a possible failure of the baroreceptor reflex... - Treatment and management of cluster headacheD W Dodick
Department of Neurology, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
Curr Pain Headache Rep 5:83-91. 2001..The cornerstone of maintenance prophylaxis is verapamil, yet methysergide, lithium, and divalproex sodium may also be employed. In some patients, melatonin or topiramate may be useful adjunctive therapies... - Thunderclap headacheD W Dodick
Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, Arizona 85259, USA
J Neurol Neurosurg Psychiatry 72:6-11. 2002..The clinical profile and differential diagnosis of thunderclap headache is described, and a nosological framework and diagnostic approach to this group of patients is proposed... - Thunderclap headacheDavid W Dodick
Department of Neurology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
Curr Pain Headache Rep 6:226-32. 2002..This has created confusion regarding nosology and the nature and extent of the diagnostic evaluation, which this article discusses... - Crossed cerebellar diaschisis during migraine with prolonged aura: a possible mechanism for cerebellar infarctionsD W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
Cephalalgia 28:83-6. 2008..This case illustrates, for the first time, crossed cerebellar diaschisis in a patient with migraine with prolonged aura, and raises the possibility that hypoperfusion may be responsible in part for the development of these lesions... - Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraineDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
CNS Drugs 21:73-82. 2007.... - Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineursDavid W Dodick
Mayo Clinic Hospital, Phoenix, Arizona 85054, USA
Clin Ther 31:542-59. 2009..The primary objective of this study was to compare the efficacy and tolerability of topiramate and amitriptyline in the prophylaxis of episodic migraine headache... - Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind studyA M Rapoport
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Neurology 69:821-6. 2007..To evaluate the efficacy and tolerability of zolmitriptan 5 mg and 10 mg nasal spray (ZNS) vs placebo in the acute treatment of cluster headache. Design/.. - Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tabletEgilius L H Spierings
Brigham and Women s Hospital, Boston, Massachusetts 02481 2106, USA
CNS Drugs 18:1133-41. 2004..To determine the speed of onset of headache response and duration of response with zolmitriptan 5 mg orally disintegrating tablet (ODT) in the acute treatment of migraine... - Refractory headaches due to multilevel thoracic cerebrospinal fluid leaksTerrence L Trentman
Departments of Anesthesiology, Mayo Clinic Arizona, Phoenix, Arizona 85054, USA
Pain Pract 8:394-8. 2008..Spontaneous cerebrospinal fluid leak is a well-documented cause of postural headache. We report a medically refractory headache due to multilevel thoracic cerebrospinal fluid leaks... - Migraine with aura is a risk factor for cardiovascular and cerebrovascular disease: a critically appraised topicDean M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
Neurologist 13:231-3. 2007..To determine whether migraine with aura and migraine without aura are independent risk factors for symptomatic cardiovascular and cerebrovascular disease... - Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project)F Michael Cutrer
Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Ther 26:1533-45. 2004..Physicians treating patients with migraine can now choose from among 7 triptans, which differ on a range of attributes that may be important for treatment selection... - Percutaneous occipital stimulator lead tip erosion: report of 2 casesTerrence L Trentman
Department of Anesthesiology, Neurology, and Neurosurgery, Mayo Clinic, Scottsdale, AZ 85054, USA
Pain Physician 11:253-6. 2008..Lead erosion is a possible complication of occipital stimulation; strategies to reduce the risk of lead erosion are discussed, although further studies are needed to clarify the best surgical techniques... - The impact of topiramate on health-related quality of life indicators in chronic migraineDavid W Dodick
Mayo Clinic College of Medicine, Department of Neurology, Scottsdale, AZ, USA
Headache 47:1398-408. 2007.... - 2007 Scottsdale Headache SymposiumBert B Vargas
Mayo Clinic, Department of Neurology, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA
Expert Rev Neurother 8:201-4. 2008.... - Stroke telemedicineBart M Demaerschalk
Department of Neurology, Mayo Clinic Hospital, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA
Mayo Clin Proc 84:53-64. 2009..The opportunities for future advances in telestroke practice, research, and education are considered... - Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trialsDavid W Dodick
Department of Neurology, Mayo Clinic Scottsdale, Ariz 85259, USA
Headache 42:21-7. 2002..01) with almotriptan 12.5 mg (31.3% to 32.0%) than with placebo (10.2% to 16.1%). CONCLUSIONS: Almotriptan 12.5 mg is significantly better than placebo and comparable to sumatriptan 100 mg for achieving a sustained pain-free state... - Cluster headache: diagnosis and treatmentRashmi Halker
Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA
Semin Neurol 30:175-85. 2010..As the sophistication of functional neuroimaging increases, better insight into the pathophysiological mechanisms that underlie cluster headache is expected... - Responsiveness of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing to hypothalamic deep brain stimulationMark K Lyons
Department of Neurological Surgery, Mayo Clinic Arizona, Pheonix, Arizona 85054, USA
J Neurosurg 110:279-81. 2009..The authors report on a case of SUNCT syndrome successfully treated with hypothalamic deep brain stimulation and discuss the current literature... - Stroke team remote evaluation using a digital observation camera in Arizona: the initial mayo clinic experience trialBart M Demaerschalk
Cerebrovascular Diseases Center, Director, Stroke Telemedicine for Arizona Rural Residents, Division of Cerebrovascular Diseases, Division of Critical Care Neurology, Department of Neurology, Mayo Clinic Hospital, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA
Stroke 41:1251-8. 2010.... - Migraine in special populations. Treatment strategies for children and adolescents, pregnant women, and the elderlyJonathan P Gladstone
Department of Neurology, Mayo Clinic Scottsdale, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
Postgrad Med 115:39-44, 47-50. 2004..In this article, Drs Gladstone, Eross, and Dodick provide pearls for both abortive and prophylactic treatments for migraine in these populations... - Occipital nerve stimulator placement under general anesthesia: initial experience with 5 cases and review of the literatureTerrence L Trentman
Department of Anesthesiology, Mayo Clinic, Phoenix, AZ 85054, USA
J Neurosurg Anesthesiol 22:158-62. 2010..Further studies are needed to correlate occipital nerve stimulator placement under general anesthesia and long-term headache control... - Greater occipital nerve stimulation via the Bion microstimulator: implantation technique and stimulation parameters. Clinical trial: NCT00205894Terrence L Trentman
Department of Anesthesiology, Mayo Clinic Arizona, Scottsdale, AZ 85054, USA
Pain Physician 12:621-8. 2009..Millions of patients suffer from medically refractory and disabling primary headache disorders. This problem has led to a search for new and innovative treatment modalities, including neuromodulation of the occipital nerves... - Diagnosis and treatment of migraineRoger Cady
Headache Care Center, Primary Care Network, Springfield, MO 65804, USA
Mayo Clin Proc 77:255-61. 2002..For prophylaxis, anticonvulsant drugs emerging as effective options are being added to the armamentarium with traditional compounds such as tricyclic antidepressants and beta-blockers... - OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programDavid W Dodick
Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ, USA
Headache 50:921-36. 2010..To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine... - Tearing without pain after trigeminal root section for cluster headacheHelen Lin
The Mayo Clinic, Scottsdale, AZ 85259, USA
Neurology 65:1650-1. 2005..These findings confirm that CH is generated by a central pacemaker and the pain may be expressed without activation of the peripheral trigeminovascular network... - Predictors of migraine headache recurrence: a pooled analysis from the eletriptan databaseDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Headache 48:184-93. 2008.... - Clinical, anatomical, and physiologic relationship between sleep and headacheDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, Ariz. 85259, USA
Headache 43:282-92. 2003..In patients with a well defined primary headache disorder, unless there are compelling historical or examination findings suggestive of a primary sleep disturbance, a formal sleep evaluation is seldom necessary... - Hemicrania continua secondary to an ipsilateral brainstem lesionMarcelo M Valença
Department of Neuropsychiatry, Federal University of Pernambuco, Recife, Brazil 50670 420
Headache 47:438-41. 2007..This case report shows anatomoclinical evidence of the involvement of brainstem structures on the pathophysiology of hemicrania continua... - Cardiovascular tolerability and safety of triptans: a review of clinical dataDavid W Dodick
Department of Neurology, Mayo Clinic Scottsdale, AZ 85359, USA
Headache 44:S20-30. 2004..Therefore, the conclusions of this review cannot be extended to patients with cardiovascular disease. The cardiovascular safety profile of triptans favors their use in the absence of contraindications... - Sumatriptan versus eletriptan: which is best?David W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
Lancet Neurol 1:474. 2002 - Epidemiology and acute care of migraine headacheDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
Manag Care Interface 17:6-10; discussion 11-3. 2004 - Thunderclap headacheDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, Ariz. 85259, USA
Headache 42:309-15. 2002 - Thunderclap headacheTodd J Schwedt
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
Lancet Neurol 5:621-31. 2006..Herein, we discuss the differential diagnosis of TCH, diagnostic criteria for the primary disorder, and proper assessment of patients. We also offer pathophysiological considerations for primary TCH... - Diagnosis and treatment of cluster headacheDavid J Capobianco
Department of Neurology, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Semin Neurol 26:242-59. 2006..As the sophistication of functional neuroimaging increases, so too will our ability to better understand the anatomic and metabolic perturbations that underlie cluster headache... - SUNCT responsive to gabapentinChristopher H Hunt
Department of Neurology, Mayo Clinic Rochester, Minn, USA
Headache 42:525-6. 2002 - The young woman with postpartum "thunderclap" headacheJonathan P Gladstone
Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
Headache 45:70-4. 2005 - Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patientsChristopher J Boes
Department of Neurology, Mayo Clinic, Rochester 55905, MN, USA
Headache 42:699-708. 2002..A consistent clinical profile and treatment response do not exclude the possibility of intracranial pathology... - Triptan nonresponder studies: implications for clinical practiceDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
Headache 45:156-62. 2005.... - Triptan-induced latent sensitization: a possible basis for medication overuse headacheMilena De Felice
Department of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, USA
Ann Neurol 67:325-37. 2010..Identification of the neural mechanisms underlying medication overuse headache resulting from triptans... - Identifying migraine in primary care settingsRichard Sadovsky
Department of Family Practice, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
Am J Med 118:11S-17S. 2005..This will result in improved functionality and decreased pain, and may help prevent disease progression... - A self-administered screener for migraine in primary care: The ID Migraine validation studyR B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Neurology 61:375-82. 2003.... - CASE 1: the well-intentioned triptan prescriberDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
Headache 48:862-4. 2008 - Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies?David W Dodick
Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ, USA
Headache 48:828-37. 2008..This review considers current debate surrounding refractory migraine and poses the question, why do some patients fail to improve with currently available therapies?.. - Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is not a cause of chronic daily headacheDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, Ariz. 85259, USA
Headache 42:547-54. 2002 - Introduction: cardiovascular safety and triptans in the acute treatment of migraineDavid W Dodick
Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA
Headache 44:S1-4. 2004 - Botulinum neurotoxin for the treatment of migraine and other primary headache disordersAndrew M Blumenfeld
Department of Neurology, Kaiser Permanente, 4405 Vandever Avenue, San Diego, CA 92120, USA
Dermatol Clin 22:167-75. 2004..Educating patients and addressing headache triggers and optimizing acute treatment improve the outcome of any preventive program... - Revised 2004 International Classification of Headache Disorders: new headache typesJonathan P Gladstone
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Can J Neurol Sci 31:304-14. 2004..i-h-s.org) for the less commonly encountered or diagnostically challenging presentations of headache and facial pain... - A not so uncommon cause of thunderclap headacheDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Headache 42:555. 2002 - Thunderclap stroke: embolic cerebellar infarcts presenting as thunderclap headacheTodd J Schwedt
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Headache 46:520-2. 2006.... - Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled studyDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Headache 45:315-24. 2005..CONCLUSIONS: BoNT-A is an effective and well-tolerated prophylactic treatment in migraine patients with CDH who are not using other prophylactic medications... - Occipital nerve stimulation for headache: mechanisms and efficacyPeter J Goadsby
Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
Headache 48:313-8. 2008..Other device-based therapies, such as deep brain stimulation for cluster headache and patent foramen ovale closure, are covered elsewhere... - Duration of migraine is a predictor for response to botulinum toxin type AEric J Eross
Mayo Clinic College of Medicine, Mayo Clinic Scottsdale, AZ 85259, USA
Headache 45:308-14. 2005..Duration of illness emerged as a predictor of treatment response. Randomized controlled studies should evaluate headache-related disability as a primary endpoint in patients with episodic and chronic headache... - Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trialStephen D Silberstein
Jefferson Headache Center, Philadelphia, PA 19107, USA
Headache 47:170-80. 2007..To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine... - Is there a preferred triptan?David W Dodick
Headache 42:1-7. 2002 - Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesisAndrew J Dowson
King s Headache Service, King s College Hospital, London, UK
CNS Drugs 19:483-97. 2005..The quality of the clinical evidence on MOH is suboptimal and further biological and clinical research is urgently required to help facilitate the management of these patients more effectively in the future... - How pain, including headache, becomes chronicDavid W Dodick
Headache 47:1272-4. 2007 - Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatmentRoger K Cady
Headache Care Center, Primary Care Network, Inc, 3805 S Kansas Expressway, Springfield, MO 65807, USA
Mayo Clin Proc 80:908-16. 2005..However, this group agreed that greater diagnostic and therapeutic attention needs to be given to patients with sinus headaches... - An otolaryngology, neurology, allergy, and primary care consensus on diagnosis and treatment of sinus headacheHoward L Levine
Cleveland Nasal-Sinus and Sleep Center, Cleveland, Ohio, USA
Otolaryngol Head Neck Surg 134:516-23. 2006..However, there was a consensus from this group that greater diagnostic and therapeutic attention needs to be given to patients complaining of sinus headache that may indeed be due to the nose... - Red ear syndromeR Allan Purdy
Division of Neurology, Department of Medicine, Dalhousie University, QEII Health Sciences Center, Halifax, Nova Scotia, B3H 3Y9, Canada
Curr Pain Headache Rep 11:313-6. 2007..As a syndrome, it still lacks specificity in regard to etiology, mechanisms, and treatment but is important to recognize clinically because of its associations... - Narrative review: reversible cerebral vasoconstriction syndromesLeonard H Calabrese
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Ann Intern Med 146:34-44. 2007..In this review, we describe our current understanding of RCVS; summarize its key clinical, laboratory, and imaging features; and discuss strategies for diagnostic evaluation and treatment... - Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trialRichard B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Lancet Neurol 9:373-80. 2010..We aimed to assess the efficacy and safety of a new portable sTMS device for acute treatment of migraine with aura... - CGRP antagonists in the acute treatment of migraineRichard B Lipton
Department of Neurology, Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY, USA
Lancet Neurol 3:332. 2004 - Painful ophthalmoplegia: overview with a focus on Tolosa-Hunt syndromeJonathan P Gladstone
Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
Curr Pain Headache Rep 8:321-9. 2004..Inflammatory conditions such as Tolosa-Hunt syndrome and orbital pseudotumor are highly responsive to corticosteroids, but should be diagnoses of exclusion... - Caffeine for the prevention and treatment of postdural puncture headache: debunking the mythRashmi B Halker
Departments of Neurology, Division of Education Services, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
Neurologist 13:323-7. 2007..Is caffeine effective in preventing and treating postdural puncture headache (PDPH)?.. - Facial painKenneth Hentschel
Mayo Clinic College of Medicine, Mayo Graduate School of Medicine, Jacksonville, FL, USA
Neurologist 11:244-9. 2005..A thorough clinical history and physical examination may reveal the characteristic clinical features and assist in diagnosis. However, in some cases, the etiology may remain indeterminate... - Migraine and cerebral white matter lesions: when to suspect cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)Jonathan P Gladstone
Mayo Clinic College of Medicine, Department of Neurology, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
Neurologist 11:19-29. 2005..The underlying pathogenesis of white matter lesions in migraineurs is unknown, and the lesions are usually nonspecific and of unclear clinical significance... - Migraine with and without aura and risk for cardiovascular diseaseBert B Vargas
Department of Neurology, Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA
Curr Atheroscler Rep 10:427-33. 2008.... - Pathophysiology and management of transformed migraine and medication overuse headacheChristopher J Boes
Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Semin Neurol 26:232-41. 2006.... - Prolonged neurologic complication and MRI abnormalities consequent to intracranial hypotensionEric J Eross
Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
Headache 43:415. 2003 - Extracephalic cluster (cluster sine headache)Esma Dilli
Mayo Clinic Arizona, 1340 East Shea Blvd, Scottsdale, AZ 85259, USA
Neurology 70:1362-3. 2008 - Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedsideDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Headache 43:S25-33. 2003..These studies may provide further evidence that botulinum toxin type A is an effective option for the preventive treatment of migraine... - Why migraines strikeDavid W Dodick
Mayo Clinic, Arizona, USA
Sci Am 299:56-63. 2008 - Spontaneous CSF leak treated with percutaneous CT-guided fibrin glueJonathan P Gladstone
Division of Neurology, University of Toronto, Canada
Neurology 64:1818-9. 2005 - Examining the essence of migraine--is it the blood vessel or the brain? A debateDavid W Dodick
Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
Headache 48:661-7. 2008..A debate is presented that examines whether it is the blood vessel or the brain that determines the essence of migraine... - Migraine and white matter hyperintensitiesAlyx Porter
University of Toronto, Division of Neurology, 1333 Sheppard Avenue East, Suite 122, M2J 1V1, Toronto, Ontario, Canada
Curr Pain Headache Rep 9:289-93. 2005..The ability to distinguish between nonspecific and disease-specific patterns of white matter hyperintensities in migraine sufferers is important for the practicing clinician...